Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Apr 2018 Status changed from recruiting to withdrawn prior to enrolment as the Reseach got cancelled.
- 02 Jan 2018 Status changed from not yet recruiting to recruiting.